Natera CFO Maps Multiple Paths to $6 Billion Revenue Target by 2029
Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”
Is Natera (NTRA) Still Cheap, Or Is Cash Flow Doing The Heavy Lifting?
ETFs Are Net Sellers of Natera (NTRA) on Wednesday
The Fund Exited Natera (NTRA) on Valuation Concerns Despite Strong Fundamentals
Strong Q2 Results and Raised Revenue Guidance Drive Natera’s (NTRA)Outperformance
Natera, Inc. (NTRA) Presents at 2026 UBS Global Healthcare Conference Transcript
Natera, Inc. (NTRA) Presents at 8th Annual Wolfe Research Healthcare Conference Transcript
Natera Enters Into Clinical Collaboration Agreement With Incyte For New Phase II Study In Colorectal Cancer
Natera Q3 Earnings Call Highlights $6B Target & Raised 2026 Outlook
NTRA Q3 2026 deep dive: management transition and pharma business investments offset margin gains
Baird Maintains Outperform on Natera, Lowers Price Target to $403
Natera (NTRA) Hands CEO Role To Longtime Insider As New Cancer Data Lands
Natera, Inc. (NTRA) Q3 2026 Earnings Call Transcript
Natera, Inc. 2026 Q3 - Results - Earnings Call Presentation
Natera Q3 Results, 2029 Revenue Target Support Growth Outlook, RBC Says
JP Morgan Maintains Overweight on Natera, Lowers Price Target to $405
Natera promotes Solomon Moshkevich to CEO
Natera Stocks Slide 15.07% After Wider Loss and Sudden CEO Change
Natera (NTRA) Q3 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.